- Home
- EXEL vs S Comparison
EXEL vs S Comparison
Compare EXEL & S Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- S
- Stock Information
- Founded
- EXEL 1994
- S 2013
- Country
- EXEL United States
- S United States
- Employees
- EXEL N/A
- S N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- S EDP Services
- Sector
- EXEL Health Care
- S Technology
- Exchange
- EXEL Nasdaq
- S Nasdaq
- Market Cap
- EXEL 9.4B
- S 8.7B
- IPO Year
- EXEL 2000
- S 2021
- Fundamental
- Price
- EXEL $37.42
- S $20.06
- Analyst Decision
- EXEL Buy
- S Buy
- Analyst Count
- EXEL 18
- S 29
- Target Price
- EXEL $37.59
- S $26.31
- AVG Volume (30 Days)
- EXEL 2.8M
- S 7.3M
- Earning Date
- EXEL 04-29-2025
- S 03-12-2025
- Dividend Yield
- EXEL N/A
- S N/A
- EPS Growth
- EXEL 170.77
- S N/A
- EPS
- EXEL 1.76
- S N/A
- Revenue
- EXEL $2,168,701,000.00
- S $821,461,000.00
- Revenue This Year
- EXEL $5.45
- S $27.82
- Revenue Next Year
- EXEL $10.32
- S $21.81
- P/E Ratio
- EXEL $21.43
- S N/A
- Revenue Growth
- EXEL 18.50
- S 32.25
- 52 Week Low
- EXEL $20.14
- S $14.33
- 52 Week High
- EXEL $40.02
- S $29.29
- Technical
- Relative Strength Index (RSI)
- EXEL 58.85
- S 47.86
- Support Level
- EXEL $36.68
- S $18.85
- Resistance Level
- EXEL $37.99
- S $19.90
- Average True Range (ATR)
- EXEL 1.09
- S 1.00
- MACD
- EXEL -0.11
- S 0.19
- Stochastic Oscillator
- EXEL 49.87
- S 81.80
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.